Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets

Table 1

Clinical features of the AS participants.

Characteristics	AS ()
Disease duration, mean ± SD years	7.9 ± 0.8
BASDAI, mean ± SD	5.25 ± 1.62
BASFI, mean ± SD	46.5 ± 23.6
CRP, mean ± SD mg/L	30.5 ± 23.5
ESR, mean ± SD mm	39.9 ± 29.5
Medications before etanercept therapy, taking/not taking
Steroids, last 3 months	6/34
DMARDs, last 3 months	27/13
NSAIDs, last 1 month	29/11

AS, ankylosing spondylitis; HC, healthy control; SD, standard deviation; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; DMARDs, disease-modifying antirheumatic drugs; NSAIDs, nonsteroidal anti-inflammatory drugs.